1810030J14Rik Activators
This gene is responsible for the production of a protein that is implicated in a range of cellular functions. To identify activators of this gene, researchers embark on a systematic screening process, employing high-throughput methods that evaluate numerous compounds for their ability to upregulate gene expression. One of the key techniques used in this phase is the reporter assay, which involves the fusion of the 1810030J14Rik gene promoter to a reporter gene like luciferase. This setup allows for the direct measurement of promoter activation through the detection of light produced by the enzymatic reaction of luciferase. When a compound interacts with the gene promoter and activates it, there is an increase in light emission, which is indicative of gene expression activation.
The compounds identified as prospective 1810030J14Rik Activators from the high-throughput screens are further scrutinized using a suite of molecular biology techniques to confirm their activity. Quantitative PCR (qPCR) is employed to determine the level of mRNA produced from the 1810030J14Rik gene. This method quantifies gene expression levels and confirms whether the mRNA transcript is being produced at higher levels in the presence of the activator compounds. Western blot analysis complements the qPCR data by measuring the level of the protein encoded by the 1810030J14Rik gene. This assay can reveal if the upregulation at the mRNA level translates into an increase in protein synthesis and can also show any changes in the protein's stability or post-translational modifications that may be induced by the activators. The integration of qPCR and Western blot results provides a comprehensive view of how these activators affect the gene expression process from transcription through to protein synthesis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA functions as a PKC activator. PKC phosphorylation of target proteins can mediate signaling pathways that result in the activation of molecular partners or modulators of 1810030J14Rik, which in turn can lead to enhanced activity of 1810030J14Rik through intracellular signaling cascades. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent protein kinases. These kinases can phosphorylate and activate proteins that are part of the signaling cascade in which 1810030J14Rik functions, indirectly increasing its activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3, which is involved in a variety of signaling pathways. Inhibition of GSK-3 can lead to activation of downstream proteins and transcription factors that may enhance the signaling processes involving 1810030J14Rik, leading to its increased activity. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a β-adrenergic agonist that increases cAMP levels via activation of adenylyl cyclase, similar to forskolin. The subsequent activation of PKA may enhance the activity of 1810030J14Rik by phosphorylating proteins that interact with or regulate 1810030J14Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit various protein kinases, which can lead to a shift in the signaling balance, potentially activating pathways that enhance the functional activity of 1810030J14Rik. | ||||||
Capsaicin | 404-86-4 | sc-3577 sc-3577C sc-3577D sc-3577A | 50 mg 250 mg 500 mg 1 g | $94.00 $173.00 $255.00 $423.00 | 26 | |
Capsaicin binds to the TRPV1 receptor, which can lead to an influx of calcium ions, activating calcium-dependent signaling pathways. These pathways might interact with or modulate the functional activity of 1810030J14Rik, leading to its activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which may reduce PI3K/Akt signaling, leading to the activation of alternate pathways or compensatory mechanisms that could enhance the activity of 1810030J14Rik. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $114.00 $175.00 $260.00 $362.00 $617.00 $1127.00 | ||
db-cAMP is a cAMP analog that activates PKA and can bypass upstream receptors and adenylyl cyclase activation. PKA can then phosphorylate target proteins in pathways involving 1810030J14Rik, potentially enhancing the protein's activity. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol has been shown to influence a variety of intracellular targets and pathways, such as sirtuins and AMPK. Activation of these proteins and pathways can lead to the modulation of signaling networks in which 1810030J14Rik might be involved, thus indirectly enhancing its functional activity. | ||||||